share_log

Cantor Fitzgerald Maintains Overweight on NeuroPace, Raises Price Target to $20

Benzinga ·  Mar 6 00:15

Cantor Fitzgerald analyst Ross Osborn maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $19 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment